TipRanks
Mativ Holdings (MX:MATV)
:MATV
Mexico Market
EarningsQ1 2026 Earnings Report

Mativ Holdings (MATV) Q1 2026 Earnings Report

0 Followers

MX:MATV Q1 2026 EPS Results

Actual EPS$1.09
Consensus EPS$0.36
Beat/MissBeat by +$0.73
One Year Ago EPS-$2.54

MX:MATV Q1 2026 Revenue Results

Actual Revenue$8.71B
Expected Revenue$8.84B
Beat/MissMissed by -$132.57M
YoY Revenue Growth-1.07%

Earnings Announcement Details

QuarterQ1 2026
Date05/06/2026
TimeAfter Close
Conference CallWednesday, May 6, 2026
MX:MATV Upcoming Earnings
Mativ Holdings's next earnings date is estimated for November 11, 2026, based on past reporting schedules.

Q1 2026 Earnings Call Audio

MX:MATV Q1 2026 Earnings Call
0:00 / 0:00

Q1 2026 Earnings Slide Deck

Q1 2026 Earnings Call Summary

Q1 2026
Earnings Call Date:May 06, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call highlighted strong operational progress: meaningful margin expansion (adjusted EBITDA up 28%, margin +220 bps), significant segment-level EBITDA gains (FAM +41%, SAS +16%), improved cash generation and successful refinancing that derisks near-term maturities. Management also executed cost-savings (~$20M realized in 2025) and outlined a formal strategic blueprint and growing commercial pipeline (notably an aerospace films win). Offsetting these positives are near-term demand weaknesses (health care destocking and a temporary plant outage), softness in release liners/labels, a substantial upward revision to expected input cost inflation ($40M–$50M) and leverage that remains above target (net debt ~$954M, net leverage 4.1x). Overall, the company presented multiple concrete actions to protect margins (pricing actions, cost savings, asset optimization) and a clear plan to continue delevering, making the tone constructive despite macro and sector-specific headwinds.
Company Guidance
Guidance highlights: Mativ expects Q2 adjusted EBITDA to be down a mid-single-digit percentage versus a strong prior year (driven largely by near-term health care volume weakness) while reiterating that pricing actions taken in January and March are intended to fully offset revised 2026 input cost inflation now estimated at $40–$50 million (up from a prior $20–$25 million view); the company is on track for $15–$20 million of cost savings in 2026 after realizing nearly $20 million in 2025, and continues to prioritize debt reduction toward a 2.5–3.5x net leverage goal (Q1 net leverage was 4.1x with net debt ≈ $954 million and liquidity ≈ $499 million); management expects annual interest expense of roughly $76 million, Q1 free cash flow was a use of $7 million (improving >$22 million YoY) against record 2025 free cash flow of $94 million with seasonally strongest cash generation expected in Q2–Q3, and the company plans modest incremental 2026 investments (~$10 million working capital and ~$5 million additional CapEx); Q1 metrics to frame this guidance: net sales $480 million, adjusted EBITDA $47.5 million (margin 9.9%, +220 bps), FAM sales $188 million with adj. EBITDA $27 million (margin 14.6%, +430 bps), SAS sales $291 million with adj. EBITDA ~ $31 million (margin 10.5%, +160 bps), and segment margins were restated ~100 bps lower after centralized cost allocations (consolidated adj. EBITDA unchanged).
Consolidated Profitability and Margin Expansion
Q1 adjusted EBITDA of $47.5M, up 28% year-over-year; adjusted EBITDA margin of 9.9%, an improvement of 220 basis points versus prior year — described as the strongest consolidated Q1 margin since the mid-2022 merger.
Strong Segment EBITDA Growth — FAM
FAM net sales of $188M (organic growth >2%); FAM adjusted EBITDA of $27M, up 41% year-over-year, with margins of 14.6% improving by 430 basis points, driven by favorable price-to-input cost ratio, lower manufacturing costs, currency tailwinds and SG&A savings.
Segment Resiliency — SAS Earnings Improvement
SAS adjusted EBITDA of ~ $31M, up ~16% year-over-year with margins of 10.5%, improving by 160 basis points, supported by favorable price-to-input cost ratio and reduced SG&A (despite SAS net sales down ~2%).
Improved Cash Flow Performance
Q1 free cash flow was a use of $7M, an improvement of >$22M year-over-year and the best Q1 cash performance since the merger; company generated record free cash flow of $94M in 2025 and remains on track for strong free cash flow in 2026.
Realized and Targeted Cost Savings
Nearly $20M of realized SG&A, operations and procurement savings in 2025; 2026 cost savings target of $15M–$20M reported to be proceeding on schedule, supporting margin expansion and cash generation.
Capital Structure Simplification and Refinancing
Refinanced majority of debt tranches in April, reduced bank group from 15 to 8, rightsized revolver to $305M, eliminated delayed draw term loan; new term loans (A $90M maturing 2031, B $500M maturing 2033) and no maturities until late 2029 — derisking near-term maturities and enhancing flexibility.
Commercial Wins and Pipeline Momentum
Secured a sizable new commitment for specialty films from a new aerospace customer (commercial relationship to commence in Q2 with shipments starting later in Q2). FAM sales pipeline materially increased year-over-year and growth seen in European filtration (aftermarket transportation, water, industrial), paint protection and industrial films; SAS growth across finished adhesive categories and commercial print.

MX:MATV Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Nov 11, 2026
2026 (Q3)
4.54 / -
7.083―
2026 (Q2)
5.08 / 9.08
5.99351.52% (+3.09)
2026 (Q1)
0.36 / 1.09
-2.542142.86% (+3.63)
2025 (Q4)
1.63 / 2.72
0.908200.00% (+1.82)
2025 (Q3)
5.63 / 7.08
3.81485.71% (+3.27)
2025 (Q2)
3.27 / 5.99
6.175-2.94% (-0.18)
2025 (Q1)
-2.09 / -2.54
0.363-800.00% (-2.91)
2024 (Q4)
0.36 / 0.91
4.177-78.26% (-3.27)
2024 (Q3)
4.99 / 3.81
3.8140.00% (0.00)
2024 (Q2)
4.18 / 6.17
9.262-33.33% (-3.09)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed